Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
September 2025
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study
RMD Open 2025;11:e005742 Doi:10.1136/rmdopen-2025-005742
In this long-term extension of the Phase 2 SLEek study, Merrill et al. report that through an additional 56-weeks of treatment, upadacitinib as monotherapy or combined with elsubrutinib demonstrated sustained or improved efficacy in multiple endpoints in patients with moderately to severely active SLE.
Keywords:
July 2025
Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies
Arthritis & Rheumatology 2025; 0:1–7 doi: 10.1002/art.43209
Exposure to voclosporin for a median of 18 months was not associated with onset or progression of nephrotoxicity based on evaluation of histologic compartments and vascular lesions. Rovin et al. characterised the impact of voclosporin on kidney histology in patients with LN who had protocolized repeat kidney biopsies in the AURORA clinical trials.
Keywords:
February 2025
Efficacy and safety of obinutuzumab in active lupus nephritis
NEJM, 2025. Epub ahead of print. DOI: 10.1056/NEJMoa2410965
Furie et al. demonstrated that obinutuzumab plus standard therapy significantly improved complete renal response at Wk76 compared with placebo. No unexpected safety signals were identified, though infections and COVID-19-related events were more frequent in the obinutuzumab group.